Ribera E, Miró J M, Cortés E, Cruceta A, Merce J, Marco F, Planes A, Paré J C, Moreno A, Ocaña I, Gatell J M, Pahissa A
Infectious Diseases Service, Hospital Vall d'Hebron, Universidad Autónoma de Barcelona, Spain.
Arch Intern Med. 1998 Oct 12;158(18):2043-50. doi: 10.1001/archinte.158.18.2043.
Immunosuppression caused by human immunodeficiency virus 1 (HIV) infection appears to modify the clinical characteristics and to increase the severity of several bacterial infections. The impact of HIV infection and the degree of immunosuppression on the clinical characteristics and outcome of infective endocarditis (IE) in intravenous (IV) drug users has not been well characterized.
Prospective cohort study among 292 consecutive IV drug users with IE diagnosed in 2 academic institutional hospitals in Barcelona, Spain, from January 1, 1984, to October 31, 1995. Serostatus of HIV infection was documented in 283 patients. We measured demographics, clinical and biological data, cause, echocardiographic findings, HIV serostatus and classification, CD4 cell count, complications, and mortality.
Among the 283 episodes of IE, 216 (76.3%) were in HIV-infected patients and 67 (23.7%) in non-HIV-infected patients. Rate of IE per 1000 admissions ranged from 0.17 to 0.82 per year, peaking in 1989. Characteristics of IE independently associated with HIV infection were right-side involvement (odds ratio [OR], 7.6; 95% confidence interval [CI], 3.5-16.7), a micro-organism different from viridans streptococci (OR, 2.5; 95% CI, 1.1-5.9), duration of drug abuse longer than 5 years (OR, 5.0; 95% CI, 2.4-10.3), and white blood cell count of no more than 10 X 10(9)/L (OR, 2.2; 95% CI, 1.1-4.2). There were no significant differences in mortality due to IE according to HIV serostatus. Among the 216 patients with HIV infection, the variables independently associated with worse outcome were CD4 cell count lower than 0.200 x 10(9)/L and left-sided or mixed IE.
Although there is a difference in clinical presentation in IE in IV drug users, outcome was similar according to their HIV status. However, among HIV-infected patients, severe immunosuppression and mixed or left-side valvular involvement were strong risk factors for mortality.
人类免疫缺陷病毒1(HIV)感染所致的免疫抑制似乎会改变临床特征,并增加几种细菌感染的严重程度。HIV感染及免疫抑制程度对静脉注射(IV)吸毒者感染性心内膜炎(IE)的临床特征及预后的影响尚未得到充分描述。
对1984年1月1日至1995年10月31日期间在西班牙巴塞罗那的2家学术机构医院连续诊断为IE的292名IV吸毒者进行前瞻性队列研究。记录了283例患者的HIV感染血清学状态。我们测量了人口统计学、临床和生物学数据、病因、超声心动图检查结果、HIV血清学状态及分类、CD4细胞计数、并发症和死亡率。
在283例IE发作中,216例(76.3%)为HIV感染患者,67例(23.7%)为非HIV感染患者。每1000例入院患者中IE的发生率每年在0.17至0.82之间,1989年达到峰值。与HIV感染独立相关的IE特征为右侧受累(优势比[OR],7.6;95%置信区间[CI],3.5 - 16.7)、不同于草绿色链球菌的微生物(OR,2.5;95% CI,1.1 - 5.9)、药物滥用持续时间超过5年(OR,5.0;95% CI,2.4 - 10.3)以及白细胞计数不超过10×10⁹/L(OR,2.2;95% CI,1.1 - 4.2)。根据HIV血清学状态,IE导致的死亡率无显著差异。在216例HIV感染患者中,与预后较差独立相关的变量为CD4细胞计数低于0.200×10⁹/L以及左侧或混合性IE。
尽管IV吸毒者IE的临床表现存在差异,但根据其HIV状态,预后相似。然而,在HIV感染患者中,严重免疫抑制以及混合性或左侧瓣膜受累是死亡的强烈危险因素。